Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This webinar provides insight into how the drug approval process affects what prescription drugs are available to patients in Canada. The presentation will cover the following topics: Who is responsible for prescription drug approval in Canada? How does the drug approval process impact patient access to medication? How can patients be involved in the drug approval process?
Please share this slideshow with anyone who may be interested!
In this webinar:
● Overview of the structure and operation of Canada’s private drug plan marketplace, including the important distinctions and/or overlaps between private (insurance) and public (government) providers
● Explanation of the role and place of medication coverage within the supplemental health benefits plans of life and health insurance companies which provide pharmaceutical coverage
● Identification of the various providers and influencers which contribute to private formulary (lists of drugs which are covered) decision-making and their roles in the system
● Understanding generally what gets covered, by which plans and under what circumstances and which medications are typically subject to restrictions
● Guidance on how to determine which medications are covered
● Exploration of how patients and caregivers can navigate through the complex private plan system including:
● Who should provide answers regarding coverage and
eligibility?
● What you can do if you run into coverage restrictions / rejections?
● How should patients interact with the private payer community generally?
Contact the presenter:
● suzanne@suzannelepage.ca
● www.suzannelepage.ca
● @suzannelepage
View the video on YouTube: https://youtu.be/yKPUT9Ymj3Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on disparities in provincial reimbursement for cancer medications, and what patients can do about it
● Explanation of the different ways that cancer treatments are managed and funded across Canada, and outline the impact this has on patients depending on where they live in the country
View the video: https://youtu.be/NN3AcGYMXac
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
This webinar provides insight into how the drug approval process affects what prescription drugs are available to patients in Canada. The presentation will cover the following topics: Who is responsible for prescription drug approval in Canada? How does the drug approval process impact patient access to medication? How can patients be involved in the drug approval process?
Please share this slideshow with anyone who may be interested!
In this webinar:
● Overview of the structure and operation of Canada’s private drug plan marketplace, including the important distinctions and/or overlaps between private (insurance) and public (government) providers
● Explanation of the role and place of medication coverage within the supplemental health benefits plans of life and health insurance companies which provide pharmaceutical coverage
● Identification of the various providers and influencers which contribute to private formulary (lists of drugs which are covered) decision-making and their roles in the system
● Understanding generally what gets covered, by which plans and under what circumstances and which medications are typically subject to restrictions
● Guidance on how to determine which medications are covered
● Exploration of how patients and caregivers can navigate through the complex private plan system including:
● Who should provide answers regarding coverage and
eligibility?
● What you can do if you run into coverage restrictions / rejections?
● How should patients interact with the private payer community generally?
Contact the presenter:
● suzanne@suzannelepage.ca
● www.suzannelepage.ca
● @suzannelepage
View the video on YouTube: https://youtu.be/yKPUT9Ymj3Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
A Rare International Dialogue (Saturday May 11, 2019)
Designing Pathways to Patient-Centered Care
Bone marrow as a Vehicle for Correction of Rare Disorders: Donna Wall, The Hospital for Sick Children
Real-World Data and Real-World Evidence Webinar
Panelists
Tara Cowling, Medlior
Laurie Lambert, CADTH
Craig Campbell, London Health Sciences
Sandra Anderson, Innomar Strategies
Brad Alyward, Canadian Organization for Rare Disorders
Durhane Wong-Rieger, Canadian Organization for Rare Disorders
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Oncology Dynamics captures a substantial part of oncological patient treatment journey. It provides real world insights into how standards of care and treatment landscape differ across healthcare systems.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Primer for attendees attending the November 15-16 Drug Pricing Policy Summit
● Broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada
● Description of legal frameworks, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement
View the video: https://youtu.be/X9AB70om-Dw
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
Gerry Jeffcott, of 360 Public Affairs, gave a presentation for the CCSN on the drug approval process in Canada on March 27, 2014. He outlines the divide between public and private networks, cost management, as well as the review and approval process for pharmaceuticals in Canada.
A Rare International Dialogue (Saturday May 11, 2019)
Designing Pathways to Patient-Centered Care
Bone marrow as a Vehicle for Correction of Rare Disorders: Donna Wall, The Hospital for Sick Children
Real-World Data and Real-World Evidence Webinar
Panelists
Tara Cowling, Medlior
Laurie Lambert, CADTH
Craig Campbell, London Health Sciences
Sandra Anderson, Innomar Strategies
Brad Alyward, Canadian Organization for Rare Disorders
Durhane Wong-Rieger, Canadian Organization for Rare Disorders
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Webinar Information:
The cancer survivor community knows the statistics about cancer all too well: that nearly half of all Canadians will develop cancer over the course of their lives, and that a quarter of them are forecasted to die from the disease. There are dozens of less prevalent cancer types that face significant and different challenges in terms of organization, research and support. The prognosis for many rare cancers is improving as new treatments are developed, however, in Canada, getting access to new therapies and clinical trials is one of many challenges faced by small communities often struggling with the disease and dealing with life’s myriad other challenges.
This webinar will explore what individual caregivers can do, how groups can work together to pool resources and share best practices and information, and provide concrete recommendations for the broader cancer community in Canada. You will learn more about how patients are working with each other, and with the clinical and research community and health systems, to improve the lives of Canadians affected by rare cancers!
Presenters:
• David Josephy, President of GIST Sarcoma Life Raft Group Canada
• Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada
• Durhane Wong-Rieger, President & CEO of the Canadian Organization for Rare Disorders (CORD)
• Bill Dempster, 3Sixty Public Affairs
View the video: https://youtu.be/L3mqpu-iFU0
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Oncology Dynamics captures a substantial part of oncological patient treatment journey. It provides real world insights into how standards of care and treatment landscape differ across healthcare systems.
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Primer for attendees attending the November 15-16 Drug Pricing Policy Summit
● Broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada
● Description of legal frameworks, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement
View the video: https://youtu.be/X9AB70om-Dw
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
The Survivor community can learn more about the state of the art in new tests available in cancer centres, which pinpoint specific types of tumours that will respond best to treatments.
Gdzie jest miejsce dla contentu w eCommerce? Shopper 3.0 Anna LasmanowiczAnna Lasmanowicz
Prezentacja Anny Lasmanowicz z konferencji Shopper 3.0 o content'cie w eCommerce, który sprzedaje na przykładzie rynków wysoko rozwiniętych i szybko się rozwijających.
Digitize It Yourself: A Method of In-House Digitization
Amanda M. Shepp, Library Director, Marion H. Skidmore Library, Lily Dale Assembly, Lily Dale, NY (Population served: 2000)
Big Talk From Small Libraries 2017
February 24, 2017
http://nlcblogs.nebraska.gov/bigtalk/
Shared Decision Making in health (Decisions Compartides) is a project of the Catalan Health Ministry of the Generalitat de Catalunya. Physicians and patients are involved in shared medical decisions. Both parties share information (evidence based information about treatment options, cons and pros, patient preferences and values) and an agreement is reached on the treatment to implement.
As new payment models emerge that emphasize value over volume, providers are being compelled to look more closely at how to motivate patients—especially those with multiple chronic conditions—to actively manage their care, make better decisions and change behaviors. This editorial webinar will explore the relationships between engagement and improved health outcomes, greater patient satisfaction and better resource utilization. Our panel of experts will share proven strategies for building patients' confidence, disseminating self-management tools and making the best use of your care team.
Patient Engagement in Health Economic and Outcomes Research: Current and Future ISPOR Initiatives, presentation from the ISPOR 20th International meeting Philadelphia, May 2015, by the Patient Centered Special Interest Group
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Utilización de la evidencia cualitativa para mejorar la inclusión de las pref...GuíaSalud
Tercera intervención de la Mesa 1 de la Jornada científica GuíaSalud 2017: La implicación de pacientes en el desarrollo de GPC. Una estrategia necesaria para mejorar la toma de decisiones. Simon Lewin
Sills MR. Overview of the SAFTINet Program. Presented to the Emergency Department Research Committee, Department of Pediatrics, University of Colorado School of Medicine. 6 January 2015.
About this Webinar: This presentation will discuss the pathway to pharmaceutical treatments in Canada that involve health technology assessment reviews and decision making. Observations on the current challenges and the importance of patient input to inform decision making will also be discussed. Finally, the key elements that can be critical to successful outcomes will be presented.
A joint presentation on Real People, Real Data at the 2016 International Forum on Quality and Safety in Healthcare in Gothenburg, Sweden. Presented by Leanne Wells of the Consumers Health Forum of Australia; Sam Vaillancourt of St. Michael’s Hospital, Toronto, Canada, and; Dr Paresh Dawda of the Australian National University.
If you're a researcher interested in Cancer Council NSW grant funding, this presentation will guide you through the application process, as well as how and why we ask you to get consumers involved.
Leonard D. Schaeffer: "Can Our Health Care System Provide a ‘Good Death’?" 9....reportingonhealth
Leonard D. Schaeffer's slides from the Center for Health Journalism webinar "Webinar: Can Our Health Care System Provide a ‘Good Death’?" 9.29.16
http://www.centerforhealthjournalism.org/content/can-our-health-care-system-provide-good-death
About the Webinar: Michelle Colero, Executive Director of Bladder Cancer Canada, will cover the essentials of bladder cancer facts and symptoms while also outlining the support and educational resources provided by Bladder Cancer Canada for those dealing with a diagnosis. Additionally, she’ll share ways individuals can contribute to raising awareness and supporting our community.
About the Webinar: Alcohol is classified as a Group one carcinogen and is estimated to be one of the top three causes of cancer deaths worldwide. Yet, over 40 per cent of people in Canada remain unaware that alcohol consumption increases the risk of developing at least nine cancers. In this presentation, we’ll look at what is and isn’t known about the relationship between alcohol and cancer. We’ll explore what the Canadian Cancer Society is doing to raise awareness of alcohol as a modifiable cancer risk factor, its commitment to funding world-leading research on this subject, and its advocacy for stronger policies that reduce, and increase awareness about the risk of cancer related to, alcohol consumption. Attendees will be invited to seek more information and/or take action on this important topic. We hope you’ll join us in learning more about cancer risk and alcohol — the most commonly used psychoactive substance in Canada.
Dr. Rob Rutledge returns for his first webinar of 2024 to discuss the basics behind emotional intelligence. Learn how to develop greater emotional awareness, and learn how to settle fear and frustration. Dr. Rutledge will also share tips on how to live in a more peaceful and connected way as you navigate through your cancer journey.
About the Webinar: Health technology assessment (HTA), the approval process for drugs and healthcare technology, the processes and organizations that support them, such as Canadian Agency for Drugs and Technologies in Health (CADTH), have evolved over the years in response to changing healthcare system priorities and the need to establish their legitimacy. Don Husereau will provide an overview of current processes in Canada, and highlight their perceived (and real) shortcomings and what can be done to overcome these. He will highlight that some perceived weaknesses (such as review times) are not as bad as they appear while perceived strengths (such as stakeholder involvement) need considerable improvement. He will also discuss other opportunities for HTA to innovate and whether there are current plans to address these.
About this Webinar: The time between regulatory approval for new drugs and when drugs became publicly available to patients averaged 736 days (25 months) in 2022. This is double the average time reported in comparable Organisation for Economic Development (OECD) countries. This webinar will highlight variations in drug listing time for new drugs across time, provinces, and type of drugs (oncology vs. non-oncology). It will also present the specific phases involved in moving a drug from approval stage to listing, and the time spent in each. This Conference Board of Canada analysis uses IQVIA’s Market Access Metrics Database (2012 to 2023), which tracks all new products and their indications through the Canadian access journey.
About the Webinar: Learn about pancreatic cancer symptoms, diagnosis, treatment options, statistics, supports and barriers. The presentation will also include some helpful tools that can improve quality of life for those with pancreatic cancer, including the Craig's Cause's PERT (Pancreatic Enzyme Replacement Therapy) calculator and available patient support programs.
As referenced by John Adams in his 2024 CCSN Webinar on the US importing drugs from Canada, this is a slide deck from Health Canada which outlines the timetable and actions taken by the government on this particular issue.
About this Webinar: John Adams takes a dive behind the headlines, news stories and media releases to better understand any real threats to Canadian patients getting the prescription drugs they need.
About this Webinar: We know that methods of eating and diet are a large part of cancer care, but how can you make your diet work for you in your cancer journey? Dr. Rob Rutelege is back to present the latest science around healthy eating and cancer care. In addition, Dr. Rutledge will share the benefits of time-restricted eating, and how you can incorporate it into your daily routine.
Colorectal cancer is the second leading cause of cancer death in Canada, with approximately 24,100 Canadians diagnosed with the disease in 2023. The incidence of colorectal cancer has been declining in Canadians over 50 years of age, largely due to population-based screening programs. Recent evidence has shown, however, that rates have been increasing in adults younger than 50 years. Given that younger adults are typically classified as at low risk for colorectal cancer, this epidemiologic shift is cause for concern.
Individuals under the age of 50 now represent a significant number of colorectal cancer cases. The disease is often being diagnosed at a later stage, and tumour characteristics tend to be more lethal. As for what is accounting for the increasing trend, ongoing research efforts focus on environmental toxicities, lifestyle patterns, and the gut microbiome.
In this webinar, we will present an overview of the current evidence surrounding the rising rates of colorectal cancer in young adults and discuss the unique needs of this patient population, through screening, diagnosis, treatment, and survivorship. A young colorectal cancer patient will share his lived experience in managing this disease and the impact that cancer has had on himself and his family.
About this Talk: This talk will provide a nutritional perspective on the role of diet in cancer focusing on healthy fats known as omega-3 fatty acids. Sources, amounts and types of omega-3 fatty acids will be highlighted. Clinical and experimental evidence in support of a role for omega-3 fatty acids in the prevention and treatment of breast cancer will be presented. Lastly, some practical strategies to support a healthy diet will be shared.
About the Webinar: Genomic testing has already become commonplace in oncology, but exponential growth in more comprehensive genomic tests, other innovative tests and testing approaches in oncology, as well as a number of other therapeutic areas is expected in the coming years. With the emergence of more complex, more expensive, and more promising tests, policymakers and healthcare providers may be challenged to provide these to patients at the pace of innovation. Don Husereau will describe what conditions are necessary for equitable access to advanced innovative testing, how major Canadian provinces are doing, and what more needs to be done in the coming years to benefit all patients.
About this Webinar: This talk will explore breast screening for women 40-49. The benefits and harms for screening will be discussed, as well as what is unique about breast cancer in women in their 40s. In order to understand the controversy around current guidelines recommending against screening women 40-49, we will review the evidence upon which these guidelines are based, and their impact on breast cancer outcomes for these women.
About this Webinar: When Canadians turn on the tap for a drink of water or a shower, we take for granted that the water is safe. Few are aware that old asbestos cement water pipes still deliver water to millions of people. As these pipes age and deteriorate, asbestos erodes into the water and poses health concerns, including cancer.
Dr. Meg Sears, Chair of the Board of Prevent Cancer Now, and board member Julian Branch will talk about the history of asbestos in water, the science behind ingested asbestos, and recent developments.
André Deschamps will show the results of the Europa UOMO Euproms studies. These are the first studies ever from patients for patients, measuring the burden of treatment. More than 5000 patients have shared with us their experiences after treatment. The data has been analyzed by the university of Rotterdam in the Netherlands and has been published in peer reviewed scientific papers.
This webinar will serve as an introduction to Cancer and Work, a website that “was designed to address the unique needs of cancer survivors with returning, remaining, changing work or looking for work after a diagnosis of cancer. The website provides newly created information, resources, and interactive tools for cancer survivors, healthcare providers, employers, and highlights helpful information from across the globe.” The talk will include 10 steps to return to work, and job search ideas for cancer survivors
This webinar will have two perspectives.
Jasveen will be presenting about the impact of cancer and treatment on a person’s physical, cognitive & mental health and how an Occupational therapist can work with the person to gradually overcome these challenges to return to work with or without modifications. The presentation will cover some case studies of past success with the opportunity to answer questions at the end.
Then we will hear from Jen who has experienced her own journey with breast cancer and how she advocated for herself and occupational therapy to help her return to full time employment.
About this Webinar: we’ll summarize the findings of a 10-minute online study conducted by Leger among cancer patients who experienced Long-COVID. We identified 119 cancer patients, diagnosed within the past 10 years, who developed symptoms or were diagnosed with Long-COVID. We primarily wanted to understand how Long-COVID impacted cancer patients and their ability to receive treatment. We also asked about the effect on their overall wellbeing, their ability to access Long-COVID treatments and assistance, and the ongoing impact to this day.
About this Presenter: Colette Faust is a Research Director at Leger (largest Canadian-owned market research company) and has 10 years of market research experience, spending the last 3 years in the healthcare industry. As a member of Leger’s North American Healthcare team, Colette has worked on both quantitative and qualitative healthcare research among healthcare professionals, patients, and the general population across a variety of topics including oncology. Colette received her B.A. in Psychology and Media & Communications from Muhlenberg College in Allentown, PA.
Various cancer treatments can impact one’s gut health and digestive system. This presentation will discuss why a healthy gut is important to overall health. We will talk about the roles the gut is involved in beyond just digestion. We will also discuss nutrition strategies that will support our gut health and promote a healthy microbiome.
In this Webinar, participants will learn about:
– Balancing rising costs and a limited budget
– Eating healthily, food banks, other resources in your community
– Budget formats that work for cancer patients
– Money management
– Debit and credit management
– Credit counselling
– Consumer protection
Canadian Immigration Tracker March 2024 - Key SlidesAndrew Griffith
Highlights
Permanent Residents decrease along with percentage of TR2PR decline to 52 percent of all Permanent Residents.
March asylum claim data not issued as of May 27 (unusually late). Irregular arrivals remain very small.
Study permit applications experiencing sharp decrease as a result of announced caps over 50 percent compared to February.
Citizenship numbers remain stable.
Slide 3 has the overall numbers and change.
ZGB - The Role of Generative AI in Government transformation.pdfSaeed Al Dhaheri
This keynote was presented during the the 7th edition of the UAE Hackathon 2024. It highlights the role of AI and Generative AI in addressing government transformation to achieve zero government bureaucracy
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
This session provides a comprehensive overview of the latest updates to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (commonly known as the Uniform Guidance) outlined in the 2 CFR 200.
With a focus on the 2024 revisions issued by the Office of Management and Budget (OMB), participants will gain insight into the key changes affecting federal grant recipients. The session will delve into critical regulatory updates, providing attendees with the knowledge and tools necessary to navigate and comply with the evolving landscape of federal grant management.
Learning Objectives:
- Understand the rationale behind the 2024 updates to the Uniform Guidance outlined in 2 CFR 200, and their implications for federal grant recipients.
- Identify the key changes and revisions introduced by the Office of Management and Budget (OMB) in the 2024 edition of 2 CFR 200.
- Gain proficiency in applying the updated regulations to ensure compliance with federal grant requirements and avoid potential audit findings.
- Develop strategies for effectively implementing the new guidelines within the grant management processes of their respective organizations, fostering efficiency and accountability in federal grant administration.
Presentation by Jared Jageler, David Adler, Noelia Duchovny, and Evan Herrnstadt, analysts in CBO’s Microeconomic Studies and Health Analysis Divisions, at the Association of Environmental and Resource Economists Summer Conference.
3. Who Pays for Pharmaceuticals in
Canada?
Total 2013 Rx Meds Expenditure
$29.3 B*; 100%
Private Sector
Share
$17.1 B; 58.4% of
total
Public Sector
Share
$12.2 B; 41.6% of
total
Other Publicly Funded Drug
Expenditure;
1.1 B; 3.8% of total;
9.0% of public share
Federal Drug Benefit Plan;
0.6 B; 2.0% of total; 4.9% of
public share
Provincial Drug
Benefit Plan;
10.5 B; 35.8% of
total; 86.1% of
public share
Out-of-Pocket
Contributions;
7.0 B; 23.9% of
total;
40.9% of private
share
Private Insurers;
10.1 B; 34.5% of
total; 59.1% of
private share
* Not including medicines dispensed in
hospitals
Source: Prescribed Drug Spending in Canada 2012
Report, CIHI
4. Complex Pathway to Patient Access
Drug Development
Health Canada
Review
Patented Medicine
Prices Review Board
Health Technology
Assessment
Hospitals
Patient Access
Private Drug
Plans
Provincial
Drug Plans
1.
5. Health Canada
• Considers clinical evidence from clinical trials
to decide if a drug/ biologic is safe and
effective for sale
• If so, the manufacturer can sell
• Monitors therapies post approval for ongoing
safety and effectiveness
6. Canadian Agency For Drugs and
Technologies in Health ( CADTH)
• Federal/provincial/ territorial health technology assessment body with two reimbursement
recommendation programs for provinces/ territories:
Common Drug Review ( CDR) program for non-cancer drugs
• Considers clinical, economic evidence and finally patient input
pan-Canadian Oncology Review ( pCODR) program for oncology drugs
• Considers clinical, economic, patient input and ease of implementation “equally” as its deliberative
framework
•
• Each decides the “value” of the drug relative to others available and relative to opportunity costs of
funding this drug versus other drugs
• Recommends a yes , a yes with conditions usually a pricing reduction or no to provincial funding bodies in
health ministries
INESSSS in Quebec
7. Provincial drug budgets
• Silos with at least one silo for drugs
• Oncology budgets are generally managed through the
cancer agencies in the province
• In Ontario and Atlantic Canada take home oncology drugs
are not paid for by the provinces but other provinces do
cover them
• Ontario has just announced an amalgamation of its Ontario
Pharmaceutical Drug Plans but no details are available yet
8. WHAT THE HTA PROCESS VALUES
Elizabeth Lye
Lymphoma Canada
10. Ethical Considerations
• Identifying values - Canada Health Act : Public
Administration; Comprehensiveness; Universality; Portability; Accessibility
• Developing framework to support identification and
analysis of ethical data to support better-informed,
value-sensitive decisions
• Training, engagement of ethicists in HTA process
• Scarcity of ethical evidence; limited resources and
expertise
11. “More” Evidence
• Incorporation of real-world evidence; patient values
• Quality of life data; lived experience of the disease
• Tools to facilitate indirect comparisons of new and/or
existing therapies
• Network meta-analysis adoption, cross-trial comparisons
• New methods for generating evidence
12. Engagement and Collaboration
• “Patient and public engagement”
• PAG input: Update to the CADTH Guidelines
for Economic Evaluation of Health
Technologies
• Clinician input: pCODR – pilot project
1.
13. CADTH Symposium Report Back
Need for change in HTA???
Sabrina Hanna
Save Your Skin Foundation
15. Evidence for everyone
Initially established as a tool for policy-makers, health
technology assessment (HTA) now supports a much
broader range of decision-makers. Everyone — whether
technology developers in academic settings and industry,
patients, clinicians, regional health authority and hospital
administrators, or private sector insurers — can benefit
from the evidence produced by HTA bodies. Because HTA
wasn’t originally designed with these stakeholders in
mind, do its processes and outputs need to change to
make it easier for clinicians, patients, and other key
stakeholders to integrate evidence into their decision-
making?
17. Numbers versus Words
• Quantitative data versus qualitative date
• Qualitative data gives a voice to the science
• Qualitative data answers the questions
1. what are the unmet needs
2. what are the experiences of the current
treatment
3. what is it like to live with the medical condition.
18. Need for Change
• Quantify qualitative data
• Create a template or guide that will help
patient groups provide input that is
meaningful and relevant
• Scientific Literacy
• Educate patient groups
19. Better decisions versus Different
Decisions
• Patient submissions help expert committees
make better decisions not different decisions
• Gap between theory and practice
20. Need for Change
• Formula/Value system for Quality of Life (QoL)
data
• Educate experts on the role of the Patient
groups
• Provide resources for patient groups to
develop submissions that are professional and
relevant to the patient experience
21.
22. Patient Centricity
• Patients Included
• Patients included charter
– Patients or caregivers actively participate in the design
and planning
– Patients and caregivers attend and participate
– Travel accommodation expenses are paid in full, in
advance. Scholarships are provided
– The disability requirement of participants are
accommodated
– Access for virtual participants is facilitated
23. Efficient HTA in real time
Health technology assessment (HTA) refers to
the systematic evaluation of properties, effects,
and/or impacts of health technology. It is a
multidisciplinary process to evaluate the social,
economic, organizational and ethical issues of a
health intervention or health technology.
• Interface of science and policy
24. Need for Change
• Join the digital age
• Share everything. hide nothing. Adapt Often
• Improvement of transparency and
communication
• Take HTA already delivered and adapt to our
setting
• Consult with people who benefit from and use
the work of HTA professionals
• Establish patient/citizen councils
28. CADTH’s Symposium in April was “certified” Patients Included
The evidence: This is a self-certification which any organization can use, providing they
meet criteria listed on the www.patientsincluded.org website.
What was missing:
Very few patients were involved in panels, and few were given scholarships to attend;
what financial support was available had to be divided between students,
preferably those presenting, and patients.
The process was unclear for patients and/or patient groups to participate in planning
the Symposium, including themes, topics and speakers, and in presenting.
There was no recognition or thanks in the program for any participation by patients.
29. CADTH obsessions
• Strong belief that patient groups are in conflict of interest if
they receive pharmaceutical company funding
• Disdainful for patients/patient groups that use Survey
Monkey or similar free or economical web-based tools to
survey patients
• Believe that patient participation is a risk: patients will be
uninformed, will belabour their own experience, will
disrupt professional decision-making
• Belief that patient input for drug reviews is suspect because
not seen as professional; lived experience is not seen as
valid
• Patient groups are questioned about their representivity
and who they report to
30.
31.
32. What is missing
• Transparency about how CADTH is funded - amounts and sources, so
patients may form their own opinions about possible bias
• Genuine understanding and respect for patient participation
• Patient pathways on CADTH website: very difficult to find out who the
patient representatives are (where they exist); how they are picked, and
for how long a term (danger of being co-opted)
• Train researchers and academic experts on value of patient input and
lived experience
• Need for critical mass: more patients, perhaps a panel of patient-experts
to be called upon in turn
• Do away with literature searches as a source of patient experiences and
work with real patients
CADTH Symposium
• Dedicated patient tables at meals and adjacent spaces so patients can
share experiences
• Serious funding to allow more patients to attend
33. The Future: best practices
internationally
Martine Elias - Myeloma Canada
Slides presented by Louise Binder
34. Our challenges are Global:
• Are regulatory decision makers able to change their
decision making paradigm?
• HTA agencies provide information and
recommendations, but then 3rd parties make the
reimbursement decisions
• What flexibility do HTA agencies have to navigate the
reimbursement environment. Will a new model be
required?
• Industry needs to address regulators, HTAs, Clinicians
and patients. Can they satisfy all?
• Bottom line: Can we manage the continuum from
bench to access in a smooth and efficient way?
1.
35. But what does Cancer Care Ontario
want….
• CCO is interested in supporting RWE that
addresses payer needs with the potential to
inform or validate funding decisions
• CCO is committed to expanding its efforts to use
RWE to inform decision making and is
management for cancer funding programs by
collaborating with their cancer partners
• They welcome input on who this could involve.
• WHERE IS THE PATIENT VOICE…
1.
36. What is being done elsewhere to bring patient value
through RWE into the decision process – EU Example
(1)
• GetReal aims to collect RWE data for early adoption in the
pharmaceutical R&D and the healthcare decision making process by:
– Bringing together healthcare decision makers, academics, pharmaceutical
companies, clinicians, and patient stakeholders;
– Proposing innovative trial designs and assessing the value of information;
– Proposing and testing innovative analytical and predictive modelling
approaches;
– Creating new decision making support, and building tools to allow for the
evaluation of development programs and use in the assessment of the
value of introducing new treatments;
– Sharing and discussing deliverables with healthcare decision makers,
academics, pharmaceutical companies, clinicians, and patient
stakeholders;
1.
37. What is being done elsewhere to bring patient value
through RWE into the decision process – EU Example
(2)
is an enabling platform for the coordination of
Medicines Adaptive Pathways to Patients (MAPPs)
activities. MAPPs seeks to foster access to beneficial
treatments for the right patient groups at the earliest
appropriate time in the product life-span in a
sustainable fashion.
1.
38. Our problems will be solved when countries can
find ways to deliver access, and manage their
uncertainty- right drug at the right time for the
right patient…
Innovative schemes to provide reimbursement
Health outcome based:
Rebate for early non-responders or pay for results
Finance disease management programs, education
Response schemes based on RWE data collection eg. Coverage with
evidence development
Provide additional data when available
Non-Outcomes based:
Population level cap
Initiation period costs
Capped duration of treatment
Volume discountIF THERE IS A WILL THERE IS A WAY>>>>>
39. Collaboration required..
• Widespread collaboration of efforts, including on an
international scale, is ideal and would support
evidence generation
• Incorporation of RWE more formally into the R&D
continuum – opportunity for every stakeholder to
cooperate (pharma, regulators, HTA, patients and
clinicians)
• Need for streamlined approach to when and how real
world evidence is considered in decision making
process
• Perhaps the development of collaborative networks
and incentivize problem solving were proposed
solutions…. Worth exploring
1.
40. A picture is worth a 1000 words…
HTA Producers
HTA evaluators
Patient
41. Recommendations from the
Symposium
Find it on the front page of the CCSN website, or
the following link:
http://survivornet.ca/en/news/what_is_cadth_a
nd_why_does_it_matter
1.
43. Canadian Cancer Survivor Network
Contact Info
Canadian Cancer Survivor Network
1750 Courtwood Crescent, Suite 210
Ottawa, ON K2C 2B5
Telephone / Téléphone : 613-898-1871
E-mail jmanthorne@survivornet.ca or mforrest@survivornet.ca
Web site www.survivornet.ca
Blog: http://jackiemanthornescancerblog.blogspot.com/
Twitter: @survivornetca
Facebook: www.facebook.com/CanadianSurvivorNet
Pinterest: http://pinterest.com/survivornetwork/